Vaccine Storage and Handling — MCQs
Assertion: VZV vaccine is live attenuated. Reason: It cannot be given to immunocompromised patients.
The efficiency of cold chain system for oral polio vaccine as monitored by Vaccine Vial Monitor (VVM) depends on:
All of the following are recognized adverse effects of DPT vaccine:
A child presented at 18 months of age who has never been vaccinated before. Which vaccines will you administer?
Which is correct about the Vaccine Vial monitor shown in the image? (Recent NEET Pattern 2016-17)
For which of the following is PPV-23 most beneficial:
What is the shelf life of Dukoral (wc-rBS) oral vaccine used for cholera prevention, when stored at a temperature of 2 °C to 8 °C?
Live vaccines are contraindicated in all except:
Ideal temperature for DPT storage?
Prevention of emergence of risk factors in a community is called:
Vaccine Storage and Handling Indian Medical PG Practice Questions and MCQs
Question 1: Assertion: VZV vaccine is live attenuated. Reason: It cannot be given to immunocompromised patients.
- A. Both true, reason doesn't explain assertion
- B. Assertion true, reason false
- C. Assertion false, reason true
- D. Both true, reason explains assertion (Correct Answer)
Explanation: ***Both true, reason explains assertion*** - The **VZV (varicella-zoster virus) vaccine** is indeed a **live attenuated vaccine** containing weakened virus - the assertion is **TRUE** - It **cannot be given to immunocompromised patients** due to risk of vaccine-strain disease - the reason is **TRUE** - The reason **directly explains the assertion**: BECAUSE the vaccine is live attenuated, it poses infection risk and therefore cannot be used in immunocompromised individuals - The **causal relationship** is clear: live attenuated nature → contraindication in immunocompromised patients *Both true, reason doesn't explain assertion* - While both statements are factually true, this option would only be correct if the reason was unrelated to the assertion - However, the reason **directly explains WHY** the live attenuated nature is clinically significant - The contraindication is a **direct consequence** of the vaccine being live attenuated, so the reason does explain the assertion *Assertion true, reason false* - The assertion is true (VZV vaccine is live attenuated) - However, the reason is also **TRUE** - live attenuated vaccines are indeed contraindicated in immunocompromised patients due to risk of disseminated vaccine-strain infection - Since both statements are true, this option is incorrect *Assertion false, reason true* - The assertion is **TRUE**, not false - VZV vaccine (Varivax, Zostavax) is a **live attenuated vaccine** containing the Oka strain - This option incorrectly claims the assertion is false - Since the assertion is factually correct, this option cannot be right
Question 2: The efficiency of cold chain system for oral polio vaccine as monitored by Vaccine Vial Monitor (VVM) depends on:
- A. Viral potency test
- B. Temperature indicator of the system
- C. Change in the colour of vaccine
- D. Change in colour of monitor (Correct Answer)
Explanation: ***Change in colour of monitor*** - The Vaccine Vial Monitor (VVM) is a label on vaccine vials that changes color progressively when exposed to heat, indicating cumulative heat exposure. - A change in the **VVM's color** signifies that the vaccine may have been exposed to temperatures that could reduce its potency and determines its usability. *Viral potency test* - A **viral potency test** directly measures the amount of live virus in a vaccine sample, which is a laboratory-based assessment and not a real-time field indicator of cold chain efficiency. - While it assesses the vaccine's actual effectiveness, it is not what the VVM monitors in the field for cold chain breaks. *Temperature indicator of the system* - A **temperature indicator** on the cold chain system itself monitors the temperature of the storage unit, not the cumulative heat exposure of individual vaccine vials. - While important for overall cold chain management, it doesn't directly indicate the heat exposure specific to a vaccine vial like a VVM does. *Change in the colour of vaccine* - A change in the **color of the vaccine** itself could indicate contamination or degradation due to various factors, not exclusively due to inadequate cold chain management as monitored by VVM. - The VVM is a separate label designed specifically to monitor heat exposure effects on the vaccine.
Question 3: All of the following are recognized adverse effects of DPT vaccine:
- A. Seizures
- B. Abscess
- C. Encephalopathy
- D. Fever (Correct Answer)
Explanation: ***Fever*** - **Fever** is the most common and expected adverse effect after DPT vaccination due to the body's normal immune response to the vaccine components. - It's usually mild and self-limiting, indicating the immune system is building protection. - Occurs in 30-50% of recipients and is considered a typical reaction rather than a complication. *Seizures* - While rare, **seizures** (febrile or afebrile) have been reported as adverse events following DPT vaccination. - Febrile seizures are more common and usually brief without long-term neurological damage. - The risk is very low (approximately 1 in 14,000 doses), and benefits far outweigh this potential risk. *Abscess* - An **abscess** at the injection site can occur as a local complication, though uncommon. - May result from improper injection technique, contamination, or local tissue reaction. - Requires medical attention and possible drainage. *Encephalopathy* - **Encephalopathy** (serious brain injury) was recognized as an extremely rare severe adverse event associated with the **whole-cell pertussis component** of older DPT vaccines. - Risk estimated at less than 1 in 1 million doses. - Modern DTaP (acellular pertussis) vaccines have largely replaced whole-cell DPT to significantly reduce this risk.
Question 4: A child presented at 18 months of age who has never been vaccinated before. Which vaccines will you administer?
- A. BCG and OPV
- B. Pentavalent vaccine alone
- C. DPT, OPV and MMR (Correct Answer)
- D. MMR, OPV, Rotavirus
Explanation: ***DPT, OPV and MMR*** - Among the given options, **DPT, OPV, and MMR** represent the **most comprehensive combination** for an unvaccinated 18-month-old child. - **DPT** provides protection against Diphtheria, Pertussis, and Tetanus (in modern practice, **Pentavalent vaccine** containing DPT+Hib+Hepatitis B is preferred). - **OPV** is essential for polio protection as part of catch-up immunization. - **MMR** (Measles, Mumps, Rubella) is critical at this age, as the first dose is typically given at 9-12 months. - **Note:** A complete catch-up schedule would also include **Hepatitis B vaccine** (if not using Pentavalent), **BCG** (if never given), and **Hib vaccine**, but this option covers the maximum number of essential vaccines among the choices provided. *BCG and OPV* - While both **BCG** and **OPV** should be part of catch-up vaccination at 18 months, this combination alone is **grossly incomplete**. - It misses critical vaccines like **DPT/Pentavalent**, **Hepatitis B**, and **MMR**. - BCG should still be given at 18 months if the child was never vaccinated, despite being ideally administered at birth. *Pentavalent vaccine alone* - **Pentavalent vaccine** (DPT+Hib+Hepatitis B) is actually preferred in modern Indian immunization practice over standalone DPT. - However, giving only Pentavalent would miss **MMR** and adequate **polio vaccination** (OPV/IPV), both of which are critical at this age. - A catch-up schedule requires multiple vaccines, not just one. *MMR, OPV, Rotavirus* - **MMR** and **OPV** are indeed essential for an 18-month-old in catch-up vaccination. - However, **Rotavirus vaccine** is **contraindicated** at this age—it must be started by 14 weeks and completed by 8 months of age (maximum age for last dose varies by vaccine brand but typically 24-32 weeks). - This combination also misses **DPT/Pentavalent** and **Hepatitis B**, making it incomplete.
Question 5: Which is correct about the Vaccine Vial monitor shown in the image? (Recent NEET Pattern 2016-17)
- A. Vaccine can be used, if expiry date not passed
- B. Vaccine can be used, after expiry date
- C. Vaccine cannot be used, irrespective of expiry date (Correct Answer)
- D. Vaccine is at discard point, consult supervisor
Explanation: ***Vaccine cannot be used, irrespective of expiry date*** - The image shows a **darker inner square** compared to the outer circle, indicating that the vaccine has been exposed to detrimental heat. - A VVM turning dark signifies that the vaccine has lost its **potency** and should not be administered, regardless of the expiry date. *Vaccine can be used, if expiry date not passed* - This statement is incorrect because the VVM clearly indicates **heat exposure** has compromised vaccine quality, making it unsuitable for use. - The VVM overrides the expiry date when it shows significant heat damage, as vaccine potency is reduced even if not expired. *Vaccine can be used, after expiry date* - This is incorrect as a vaccine should never be used **after its expiry date**, irrespective of the VVM status, as sterility and potency cannot be guaranteed. - Using expired vaccines poses a **health risk** and may not provide adequate protection. *Vaccine is at discard point, consult supervisor* - While it is at the discard point, consulting a supervisor is not the primary instruction; the vaccine is simply **unsuitable for use**. - The VVM is designed to be a **clear indicator** for immediate action, not necessarily requiring further consultation for the general health worker.
Question 6: For which of the following is PPV-23 most beneficial:
- A. Child less than 2 years
- B. Sickle cell anemia patient (Correct Answer)
- C. Cystic fibrosis patient
- D. Patient with recurrent rhinitis and sinusitis
Explanation: ***Sickle cell anemia patient*** - Individuals with **sickle cell anemia** are at a **high risk of invasive pneumococcal disease** due to functional asplenia, making PPV-23 highly beneficial for them. - The **PPV-23 vaccine** targets 23 serotypes of *Streptococcus pneumoniae* and is recommended for those aged 2 years and older with certain chronic medical conditions, including sickle cell disease. - This is one of the **strongest indications** for PPV-23 due to the severe immunocompromise from splenic dysfunction. *Child less than 2 years* - The **polysaccharide vaccines** like PPV-23 are generally **not effective in children younger than 2 years** as their immature immune system does not respond well to polysaccharide antigens. - For children in this age group, the **pneumococcal conjugate vaccine (PCV13)**, which elicits a T-cell-dependent immune response, is recommended. *Cystic fibrosis patient* - While patients with **cystic fibrosis** are at increased risk for respiratory infections, the primary pathogens are typically *Pseudomonas aeruginosa* and *Staphylococcus aureus*, not *Streptococcus pneumoniae*. - Although pneumococcal vaccination (including PPV-23) is generally recommended for individuals with chronic lung disease, it is **not as specifically indicated or beneficial as for sickle cell patients** who demonstrate profoundly impaired splenic function. *Patient with recurrent rhinitis and sinusitis* - **Recurrent rhinitis and sinusitis** are commonly caused by **viral infections**, allergies, or anatomical abnormalities, not typically by serious invasive pneumococcal disease against which PPV-23 offers protection. - While some episodes might involve *Streptococcus pneumoniae*, this condition does not place a patient in the same **high-risk category for severe, invasive pneumococcal infections** that would mandate PPV-23 vaccination as a primary intervention.
Question 7: What is the shelf life of Dukoral (wc-rBS) oral vaccine used for cholera prevention, when stored at a temperature of 2 °C to 8 °C?
- A. 2 years (Correct Answer)
- B. 3 years
- C. 6 months
- D. 5 years
Explanation: ***2 years***- Dukoral (wc-rBS) oral vaccine, when stored correctly at **2 °C to 8 °C**, maintains its efficacy and stability for **2 years**. - This is the manufacturer-specified shelf life that ensures the vaccine remains potent and safe for use. - The vaccine contains inactivated whole-cell V. cholerae and recombinant cholera toxin B subunit, with a validated 2-year stability period. *3 years*- A 3-year shelf life is an **overestimation** for Dukoral under standard refrigerated storage conditions. - Beyond the validated 2-year period, the vaccine's potency cannot be guaranteed. - This could lead to administration of potentially ineffective vaccine. *6 months*- A 6-month shelf life is significantly **underestimated** for Dukoral, indicating a lack of understanding of vaccine stability. - Such a short duration would lead to premature discarding of usable vaccine and increased waste. - Most modern refrigerated vaccines have longer shelf lives than this. *5 years*- A 5-year shelf life is a significant **overestimation** for Dukoral (wc-rBS). - This duration exceeds the manufacturer's validated stability data for this oral vaccine. - Using vaccine beyond its validated shelf life poses risks of reduced immunogenicity.
Question 8: Live vaccines are contraindicated in all except:
- A. Breastfeeding mothers (Correct Answer)
- B. Pregnant women
- C. Immunocompromised patients
- D. Patients on high-dose immunosuppressants
Explanation: ***Breastfeeding mothers*** - Live vaccines are generally **safe for breastfeeding mothers** and their infants, as the vaccine viruses are not typically excreted in breast milk in levels that can infect the infant. - The benefits of vaccinating the mother outweigh any theoretical risks, and it can provide **passive immunity** to the infant through antibodies in breast milk. *Pregnant women* - Live vaccines are **contraindicated during pregnancy** due to the theoretical risk of transmitting the attenuated virus to the fetus and causing congenital infection. - Examples include **MMR** and **varicella vaccines**, which should be administered before or after pregnancy. *Immunocompromised patients* - Live vaccines are **contraindicated** in individuals with compromised immune systems due to the risk of the attenuated vaccine virus causing **disseminated infection** or severe disease. - This includes patients with **HIV/AIDS** (with low CD4 counts), congenital immunodeficiencies, and those undergoing active cancer treatment. *Patients on high-dose immunosuppressants* - These patients are considered **immunocompromised**, and live vaccines are **contraindicated** because their suppressed immune system may not be able to effectively control the attenuated vaccine virus, leading to severe infection. - Examples of such medications include high-dose corticosteroids, chemotherapy agents, and biologics that target immune cells.
Question 9: Ideal temperature for DPT storage?
- A. Room temperature
- B. 4 to 8°C (Correct Answer)
- C. 0 to - 20°C
- D. None of the options
Explanation: ***4 to 8°C*** - The ideal temperature for DPT (diphtheria, pertussis, tetanus) vaccine storage is between **+2°C and +8°C** (or 35°F and 46°F), which is the standard refrigerator temperature range. - This temperature range is crucial for maintaining the **potency** and **efficacy** of the vaccine, preventing **degradation** due to excessive heat or cold. *Room temperature* - Storing DPT vaccines at **room temperature** (typically 20-25°C or 68-77°F) for extended periods can lead to a **loss of potency** as heat can degrade vaccine components. - While short-term excursions within this range might be permissible under specific conditions (e.g., during transport), it is not the ideal long-term storage solution. *0 to - 20°C* - DPT vaccines, particularly the **whole-cell pertussis (wP)** component, can be **damaged by freezing**. - Temperatures below 0°C can cause the **adjuvant** (usually aluminum salt) to separate, leading to a loss of efficacy and potential local reactions at the injection site. *None of the options* - This option is incorrect because **4 to 8°C** is indeed the established and recommended ideal storage temperature for DPT vaccines.
Question 10: Prevention of emergence of risk factors in a community is called:
- A. Primordial prevention (Correct Answer)
- B. Secondary prevention
- C. Tertiary prevention
- D. Primary prevention
Explanation: ***Primordial prevention*** - This level of prevention focuses on preventing the **emergence or development of risk factors** themselves in a community. - It targets underlying **social, economic, and environmental conditions** that contribute to risk factor development. - Examples include policies to prevent smoking initiation in youth or promoting healthy dietary patterns before diseases emerge. *Primary prevention* - This involves **preventing disease occurrence** by controlling risk factors that already exist. - Examples include **vaccination**, health education, and lifestyle modifications (e.g., promoting exercise to prevent obesity). - Differs from primordial as it addresses established risk factors rather than preventing their emergence. *Secondary prevention* - This involves **early detection and prompt treatment** of diseases to prevent their progression. - Examples include **screening programs** (e.g., mammography for breast cancer) and regular blood pressure checks. *Tertiary prevention* - This aims to **reduce the impact of an established disease** and prevent disability or complications through rehabilitation. - Examples include **physical therapy** after a stroke or support groups for chronic illnesses.
Want unlimited practice?
Get full access to all questions, explanations, and performance tracking.
Start For Free